Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The impact of non-adherence to medication in patients with schizophrenia on health, social care and societal costs. Analysis of the QUATRO study.

King D, Knapp M, Patel A, Amaddeo F, Tansella M, Schene A, Koeter M, Angermeyer M, Becker T.

Epidemiol Psychiatr Sci. 2014 Mar;23(1):61-70. doi: 10.1017/S2045796013000097. Epub 2013 Apr 10.

PMID:
23574732
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.
4.

Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.

Loosbrock DL, Zhao Z, Johnstone BM, Morris LS.

J Ment Health Policy Econ. 2003 Jun;6(2):67-75.

PMID:
14578539
5.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

6.

Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.

Barbui C, Nosè M, Mazzi MA, Bindman J, Leese M, Schene A, Becker T, Angermeyer MC, Koeter M, Gray R, Tansella M.

Int Clin Psychopharmacol. 2006 Mar;21(2):73-9.

PMID:
16421457
7.

Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.

Hansen RA, Maciejewski M, Yu-Isenberg K, Farley JF.

Psychiatr Serv. 2012 Sep 1;63(9):920-8. doi: 10.1176/appi.ps.201100328.

PMID:
22706887
8.

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV.

Am J Psychiatry. 2004 Apr;161(4):692-9.

PMID:
15056516
9.

Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries.

Patel A, McCrone P, Leese M, Amaddeo F, Tansella M, Kilian R, Angermeyer M, Kikkert M, Schene A, Knapp M.

Cost Eff Resour Alloc. 2013 May 25;11(1):12. doi: 10.1186/1478-7547-11-12.

10.

Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.

Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW.

J Manag Care Pharm. 2006 Jan-Feb;12(1):43-54.

11.

Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study.

Puschner B, Born A, Giessler A, Helm H, Leese M, Bindman JP, Gray RJ, Schene A, Kikkert M, Burti L, Marrella G, Becker T.

J Nerv Ment Dis. 2006 Oct;194(10):746-52. Erratum in: J Nerv Ment Dis. 2006 Dec;194(12):904. Giebler, Anne [corrected to Giessler, Anne].

PMID:
17041286
12.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
13.

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.

Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.

Value Health. 2004 Jan-Feb;7(1):22-35.

14.

Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW.

J Clin Psychiatry. 2006 Mar;67(3):453-60.

PMID:
16649833
15.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133
16.

Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

Knapp M, King D, Pugner K, Lapuerta P.

Br J Psychiatry. 2004 Jun;184:509-16.

18.
19.

Associations between statin adherence level, health care costs, and utilization.

Zhao Y, Zabriski S, Bertram C.

J Manag Care Spec Pharm. 2014 Jul;20(7):703-13.

20.

Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.

Hong J, Novick D, Brugnoli R, Bertsch J, Haro JM.

Hum Psychopharmacol. 2013 Sep;28(5):438-46. doi: 10.1002/hup.2328. Epub 2013 Jun 15.

PMID:
23775950
Items per page

Supplemental Content

Write to the Help Desk